share_log

Credit Suisse Maintains Outperform on Pear Therapeutics, Lowers Price Target to $7

Credit Suisse Maintains Outperform on Pear Therapeutics, Lowers Price Target to $7

瑞士信贷维持Pear Therapeutics的跑赢大盘,将目标股价下调至7美元
Benzinga Real-time News ·  2022/11/15 09:02

Credit Suisse analyst Judah Frommer maintains Pear Therapeutics (NASDAQ:PEAR) with a Outperform and lowers the price target from $9 to $7.

瑞士信贷分析师Judah Frommer维持Pear Therapeutics(纳斯达克股票代码:PEAR)的跑赢大盘,并将目标股价从9美元下调至7美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发